ESALF News and Press, Eisai Co Ltd From 06/07/21

Photo by selvanegra/iStock via Getty Images Biogen ([[BIIB]] +0.3%) shares have reached the highest level in the year so far as the investors eagerly await the FDA decision on aducanumab, the experimental therapy against Alzheimer’s disease. The FDA set a new action date for June 07 wh...

Photo by selvanegra/iStock via Getty Images Biogen (BIIB) rose ~5.0% on Friday to outperform the broader market for the week as it awaits FDA approval for aducanumab, the experimental therapy against Alzheimer’s disease co-developed by the company with Eisai (ESALF)...

Wall Street has turned its attention on Biogen ([[BIIB]] +0.4%) ahead of the FDA action date on June 07 for the experimental Alzheimer’s therapy aducanumab co-developed by the company in partnership with Eisai ([[ESALF]]).Without sufficient preparation for a patent cliff for three mult...

iRhythm cut to neutral at Citi on leadership transitionReaffirmed guidance for the current quarter did not help iRhythm Technologies (IRTC) to avert a sharp selloff in the post-market yesterday after announcing the departure of its CEO Michael Coyle effective June 01.The stock has e...

The scientists, public advocacy groups, and analysts offer contrasting views as FDA is set to decide on aducanumab, the experimental therapy co-developed by Biogen (BIIB) and Japanese pharmaceutical company Eisai (ESALF) against Alzheimer’s disease.The marketing application for aducanu...

A majority of Biogen ([[BIIB]] -1.8%) investors predict the company to win the FDA approval for experimental Alzheimer’s disease therapy aducanumab albeit with restrictions, according to a survey conducted by RBC Capital Markets.With restrictive monitoring requirements, the FDA approva...

Recent advances in understanding how soluble amyloid oligomers drive Alzheimer’s disease and new biomarkers are supporting the development of effective treatments that will reach the market in the near future. These scientific developments also provide a new way for investors t...

Eisai Co., Ltd. (ESALF) Q4 2021 Earnings Conference Call May 12, 2021 03:00 AM ET Company Participants Haruo Naito - CEO Ryohei Yanagi - EVP & CFO Ivan Cheung - SVP & President of Neurology Business Group Takashi Owa - Chief Medicine Creation Officer & Chief Discovery Officer Onco...

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Eisai Co., Ltd. 2021 Q4 - Results - Earnings Call Presentation

Eisai (ESALF): FY GAAP EPS of ¥146.90.Revenue of ¥645.94B (-7.1% Y/Y)FY2021 guidance: Revenue of ¥681B; Profit for the year of ¥45BPress Release For further details see: Eisai reports FY results, provides outlook